MedCap AB (SE:MCAP)
:MCAP
Want to see SE:MCAP full AI Analyst Report?
Top Page
MedCap AB
(MCAP)
Select Model
Select Model
Rating:69Neutral
Price Target:
kr525.00
▼(-1.50% Downside)
Action:ReiteratedDate:05/01/26
The score is driven primarily by solid financial performance (strong revenue momentum and healthy margins) tempered by margin volatility, rising leverage, and uneven cash conversion. Technicals are weak-to-neutral with the stock trading below key moving averages, and valuation looks relatively expensive on a ~31.9 P/E with no dividend yield provided.
Positive Factors
Revenue and Margin Strength
Sustained TTM revenue and mid-teens EBIT margins indicate durable earnings power across the group. Consistent profitability supports reinvestment into subsidiaries, funds add-on buyouts and operational improvements, and underpins ability to fund growth without relying solely on external capital.
Negative Factors
Gross Margin Volatility
Large swings in gross margin reduce visibility into sustainable profitability and complicate medium-term planning. Such volatility can stem from one-offs, pricing or input-cost shifts, and if persistent it undermines forecasting, investment decisions and the ability to consistently improve operating margins across portfolio companies.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and Margin Strength
Sustained TTM revenue and mid-teens EBIT margins indicate durable earnings power across the group. Consistent profitability supports reinvestment into subsidiaries, funds add-on buyouts and operational improvements, and underpins ability to fund growth without relying solely on external capital.
Read all positive factors
MedCap AB (MCAP) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr7.23B
Dividend YieldN/A
Average Volume (3M)21.82K
Price to Earnings (P/E)31.9
Beta (1Y)0.65
Revenue Growth18.06%
EPS Growth10.57%
CountrySE
Employees570
SectorHealthcare
Sector Strength45
IndustryAsset Management
Share Statistics
EPS (TTM)4.57
Shares Outstanding15,077,583
10 Day Avg. Volume14,106
30 Day Avg. Volume21,821
Financial Highlights & Ratios
PEG Ratio7.70
Price to Book (P/B)5.67
Price to Sales (P/S)3.90
P/FCF Ratio29.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)22.26
Revenue Forecast (FY)kr2.31B
MedCap AB Business Overview & Revenue Model
Company Description
MedCap AB (publ) is a private equity firm specializing in investments in secondary direct, later stage, industry consolidation, growth capital, middle market, mature, turnarounds, buyout. It prefers to invest in healthcare equipment and services, ...
How the Company Makes Money
MedCap makes money primarily through the operating revenues and profits generated by its portfolio companies. The core revenue model is therefore consolidated sales of medical-technology and life-science products and services sold by its subsidiar...
MedCap AB Financial Statement Overview
Summary
Income Statement
84
Very Positive
Balance Sheet
78
Positive
Cash Flow
72
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.17B | 2.11B | 1.81B | 1.59B | 1.11B | 916.30M |
| Gross Profit | 808.20M | 321.00M | 1.06B | 926.40M | 462.40M | 369.80M |
| EBITDA | 496.50M | 473.90M | 396.00M | 341.90M | 237.30M | 191.50M |
| Net Income | 225.30M | 219.80M | 207.40M | 172.20M | 117.60M | 96.50M |
Balance Sheet | ||||||
| Total Assets | 2.70B | 2.61B | 1.99B | 1.66B | 1.43B | 1.17B |
| Cash, Cash Equivalents and Short-Term Investments | 394.40M | 370.40M | 370.10M | 188.20M | 236.20M | 139.70M |
| Total Debt | 478.10M | 707.00M | 358.00M | 261.20M | 340.00M | 256.90M |
| Total Liabilities | 1.17B | 1.15B | 703.20M | 635.10M | 570.60M | 471.80M |
| Stockholders Equity | 1.53B | 1.45B | 1.28B | 1.02B | 856.30M | 696.00M |
Cash Flow | ||||||
| Free Cash Flow | 294.60M | 280.50M | 293.80M | 188.70M | 41.20M | 55.40M |
| Operating Cash Flow | 338.90M | 342.70M | 360.00M | 228.00M | 85.50M | 116.30M |
| Investing Cash Flow | -337.10M | -391.30M | -128.80M | -152.30M | -56.10M | -64.80M |
| Financing Cash Flow | 67.00M | 52.20M | -46.10M | -119.70M | 61.20M | -64.10M |
MedCap AB Technical Analysis
Positive
533.00
Price Trends
482.25
Positive
506.51
Positive
548.31
Negative
Market Momentum
7.83
Negative
63.85
Neutral
90.52
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:MCAP, the sentiment is Positive. The current price of 533 is above the 20-day moving average (MA) of 479.04, above the 50-day MA of 482.25, and below the 200-day MA of 548.31, indicating a neutral trend. The MACD of 7.83 indicates Negative momentum. The RSI at 63.85 is Neutral, neither overbought nor oversold. The STOCH value of 90.52 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:MCAP.
MedCap AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | kr6.51B | 3.42 | ― | 6.23% | 2.88% | 256.86% | |
69 Neutral | kr7.23B | 31.86 | 15.16% | ― | 18.06% | 10.57% | |
63 Neutral | kr9.64B | -4.79 | 11.24% | 2.18% | 8.58% | -60.72% | |
56 Neutral | kr4.26B | -5.81 | -1.58% | ― | 21.43% | 71.67% | |
55 Neutral | kr5.45B | -3.58 | 7.55% | 0.79% | -191.26% | -204.37% | |
53 Neutral | kr19.80B | -7.93 | -23.18% | 1.13% | 23.33% | -181.45% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
SE:MCAP
MedCap AB
479.80
44.80
10.30%
SE:CRED.A
Creades AB
71.00
-4.52
-5.99%
SE:BURE
Bure Equity AB
267.00
-54.18
-16.87%
SE:LINC
Linc AB
73.60
6.61
9.87%
SE:SVOL.B
Svolder AB Class B
51.50
-4.55
-8.12%
SE:ORES
Investment AB Oresund
143.20
32.25
29.07%
MedCap AB Corporate Events
MedCap Delivers Strong Q1 2026 With Higher Sales and Margins
Apr 29, 2026
MedCap AB, a Swedish healthcare-focused group, reported a strong first quarter for 2026, driven by higher sales and improved profitability across its operations. The company continues to emphasize EBITA and margin performance as key indicators of ...
MedCap Delivers Strong Q4 and Full-Year 2025 Growth With Sharply Higher Margins
Feb 6, 2026
MedCap AB reported strong growth for the fourth quarter of 2025, with net sales up 25% to SEK 591.0 million and EBITA rising 73% to SEK 122.1 million, lifting the EBITA margin to 20.7%. On an adjusted basis, EBITA grew 68% and the margin improved ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.